CaroGen Corp is a biotechnology company based in Hamden, Town of, CT. They have developed the innovative AVIDIO platform, which utilizes RNA-based artificial viruses to deliver multiple transgenes and generate a broad spectrum of immune responses, with a focus on immuno-oncology. CaroGen Corp has two candidates in late-stage pre-clinical IND enabling studies, CARG-2020 for ovarian cancer and CARG-201 for Chronic Hepatitis B, and boasts a growing patent portfolio supported by over $10 million in NIH and DoD grants.
With a team of experienced founders and scientific advisors, CaroGen Corp is dedicated to advancing their AVIDIO platform and developing novel immunotherapies for infectious diseases and oncology. They have collaborated with prestigious institutions such as Wayne State University and UConn Health, and their groundbreaking research has been presented at various conferences and published in scientific journals. CaroGen Corp is committed to making significant progress in the field of immunotherapy and aims to provide potential functional cures for millions of patients worldwide.
Generated from the website